February 10, 2025 7:45am
Still “game” sober, as earnings are a’comin
While nothing has slowed this bull market rally, history has often shown that when things seem too good to be true, they usually are…
The return of Trump to the White House will strike the difference
Pre-open Indications: 2 Positive and 3 Negative
Earnings Dates: SAGE, ALNY, BPMC, MRNA, IONS, RARE and MDXG <in the Bottom Line>
To watch more insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!
Friday’s night’s … RegMed Investors (RMi) Closing Bell: Sector share pricing wipe-out … https://www.regmedinvestors.com/articles/13796
Monday; the pre-open Dow futures are UP +0.44% or (+197 points), the S&P futures UP +0.43% or (+25 points) and the Nasdaq futures are UP +0.64% or (+137 points)
- Stock futures rise to start the week,
- European stock markets started the week on a positive note, appearing to shrug off President Trump’s latest tariff announcement,
- Asia-Pacific markets mixed in choppy trade as tariff threats keep investors on edge
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Indexes slid on Friday as a mix of news related to tariffs and inflation worried traders to close out the week.
The Dow fell 444.23 points, or 0.99%, to close at 44,303.40. The S&P 500 declined 0.95% to 6,025.99, and the Nasdaq slid 1.36% to end at 19,523.40. Friday’s losses left the major averages in negative territory on the week.
Economic Data Docket: None
Q1/25: February – 3 negative and 2 positive closes
- January – 2 holidays, 1 market close, 10 negative and 10 positive closes
Q4/24:
- December 1 holiday, 15 negative and 5 positive closes
- November 10 negative and 9 positive closes
- October: 8 positive and 15 negative closes
52-week low:
- Solid Biosciences (SLDB) at $2.89
- Prime medicine (PRME) at $2.49
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Negative:
Alnylam Pharmaceuticals (ALNY closed down -$2.69 with a negative -$1.08 0r -0.39 pre-open
Lenz Therapeutics (LENZ) closed down -$1.41 with a negative -0.27 or -1.07% pre-open
AxoGen (AXGN) closed down -$0.37 with a negative -$1.25 or -6.95% pre-open
Mesoblast (MESO) closed UP +$0.80 with a negative -$0.47 or -2.41% pre-open
Positive:
Beam therapeutics (BEAM) closed down -$0.24 with a positive +0.29 or +1.06% pre-open
Vericel (VCEL) closed down -$1.35 with a positive +$1.29 or +1.06% pre-open
The BOTTOM LINE: prepare for more market volatility related to earnings uncertainty …
February ‘25: understand the “flow” …
- 2/7 – Friday ended with a negative close at the close of 2 incliner, 31 decliners and 2 flats
- 2/6 – Thursday ended with a negative close at the close of 8 incliner, 24 decliners and 3 flats
- 2/5 - Wednesday ended with a positive close at the close of 26 incliner, 4 decliners and 5 flats
- 2/4 - Tuesday ended with a positive close at the close of 24 incliner, 9 decliners and 2 flats
- 2/3 – Monday - ended with a negative close at the close of 8 incliner, 25 decliners and 2 flats
Earnings are a-comin’ … from Q4/24 and FY24 are due …
- Sage Therapeutics (SAGE) - Tuesday, 2/11
- Blueprint Medicine (BPMC) – Thursday, 2/13
- Alnylam Pharmaceuticals (ALNY), Thursday, 2/13
- Ultragenyx Pharmaceuticals (RARE). Thursday, 2/13
- Moderna (MRNA) - Friday, 2/14
- Ionis pharmaceuticals IONS) – Wednesday, 2/19
- MiMedx (MDXG) – Wednesday, 2/26
What could 2025 have in store for the capital access space as Partners are the gift of life!
- "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.
I seem to be asking a question followed by a question …
- Do we need to brace ourself for more economics and their down trending affect?
- Is this market STILL “bubblicious” my concerns are macroeconomic and valuation
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
